Skip to main content

Lexaria Bioscience Corp. (LEXX)

NASDAQ: LEXX · IEX Real-Time Price · USD
6.75 0.01 (0.15%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap39.00M
Revenue (ttm)825,456
Net Income (ttm)-3.56M
Shares Out5.10M
EPS (ttm)-0.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,342
Open6.70
Previous Close6.74
Day's Range6.65 - 6.83
52-Week Range3.98 - 12.50
Beta1.51
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About LEXX

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

IndustryBiotechnology
Founded2004
Employees4
Stock ExchangeNASDAQ
Ticker SymbolLEXX
Full Company Profile

Financial Performance

In 2020, LEXX's revenue was $384,543, an increase of 72.74% compared to the previous year's $222,610. Losses were -$4.08 million, -1.77% less than in 2019.

Financial Statements

News

Lexaria's Technology Proven to Deliver Oral THC More Effectively

DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...

1 week ago - Accesswire

DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete

New York, New York--(Newsfile Corp. - October 5, 2021) - PCG Digital -- Lexaria Bioscience Corp (NASDAQ: LEXX) is making headlines again this week. In a study conducted by a leading independent testing ...

2 weeks ago - Newsfile Corp

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 / Lexaria Bio...

2 weeks ago - Accesswire

Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that Chair...

1 month ago - Accesswire

Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension

Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH-processed cannabidiol (DehydraTECH-CBD...

1 month ago - Benzinga

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "...

1 month ago - Accesswire

BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs

Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and br...

1 month ago - Newsfile Corp

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, S...

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX's patented DehydraTECH(TM)-processed cannab...

1 month ago - Benzinga

Why Lexaria Bioscience Shares Are Trading Higher Today

Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study evidences up to 23% decrease i...

1 month ago - Benzinga

Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertensi...

1 month ago - Benzinga

Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory P...

Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria Bios...

1 month ago - Accesswire

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Del...

Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodst...

1 month ago - Benzinga

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience Corp...

2 months ago - Accesswire

DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores

Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)...

2 months ago - Accesswire

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in d...

2 months ago - Accesswire

Lexaria Receives US$3,817,643 From Warrant Exercises

KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the rec...

2 months ago - Accesswire

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

All objectives evaluating DehydraTECH ™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Le...

2 months ago - Accesswire

Why Lexaria Bioscience Is Surging Today

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are trading higher after the company announced its DehydraTECH significantly enhances delivery of colchicine in study VIRAL-A20-3. This study demonstrated t...

3 months ago - Benzinga

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexari...

3 months ago - Accesswire

Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the Nati...

3 months ago - Benzinga

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), ...

3 months ago - Accesswire

Lexaria Receives Patent Protection in Japan

New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Compan...

3 months ago - Accesswire

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capi...

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on Jun...

3 months ago - Accesswire

Lexaria Announces 2021 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results...

3 months ago - Accesswire

Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)

New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vit...

4 months ago - Newsfile Corp